Gaucher disease
- 1 August 2007
- journal article
- review article
- Published by Elsevier in Current Opinion in Chemical Biology
- Vol. 11 (4) , 412-418
- https://doi.org/10.1016/j.cbpa.2007.05.035
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Enzyme enhancement activity of N-octyl-β-valienamine on β-glucosidase mutants associated with Gaucher diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2007
- EDEM1 reveals a quality control vesicular transport pathway out of the endoplasmic reticulum not involving the COPII exit sitesProceedings of the National Academy of Sciences, 2007
- High-Throughput Screening for Human Lysosomal β-N-Acetyl Hexosaminidase Inhibitors Acting as Pharmacological ChaperonesChemistry & Biology, 2007
- Isofagomine- and 2,5-Anhydro-2,5-imino-d-glucitol-Based Glucocerebrosidase Pharmacological Chaperones for Gaucher Disease InterventionJournal of Medicinal Chemistry, 2006
- Selective action of the iminosugar isofagomine, a pharmacological chaperone for mutant forms of acid-β-glucosidaseBiochemical Pharmacology, 2006
- Effective cell and gene therapy in a murine model of Gaucher diseaseProceedings of the National Academy of Sciences, 2006
- The iminosugar isofagomine increases the activity of N370S mutant acid β-glucosidase in Gaucher fibroblasts by several mechanismsProceedings of the National Academy of Sciences, 2006
- Substrate reduction therapy of glycosphingolipid storage disordersJournal of Inherited Metabolic Disease, 2006
- The cell biology of lysosomal storage disordersNature Reviews Molecular Cell Biology, 2004
- Preparation, biochemical characterization and biological properties of radiolabelled N-alkylated deoxynojirimycinsBiochemical Journal, 2002